1.
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple the...
by Malfertheiner, Peter, Prof
The Lancet (British edition), 2011, Vol.377 (9769), p.905-913
2.
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial
by Liou, Jyh-Ming, MD
The Lancet (British edition), 2016, Vol.388 (10058), p.2355-2365
3.
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial
by Liou, Jyh-Ming, MD
The Lancet (British edition), 2013, Vol.381 (9862), p.205-213
4.
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial
by Greenberg, E Robert, Dr
The Lancet (British edition), 2011, Vol.378 (9790), p.507-514
5.
Helicobacter pylori therapy: a paradigm shift
by Graham, David Y.
Expert review of anti-infective therapy, 2016, Vol.14 (6), p.577-585
6.
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study
by Molina‐Infante, J.
Alimentary pharmacology & therapeutics, 2015, Vol.41 (6), p.581-589
7.
8.
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial
by Romano, Marco
Gut, 2010, Vol.59 (11), p.1465-1470
9.
Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility
by Okubo, Hidetaka
Journal of gastroenterology, 2020, Vol.55 (11), p.1054-1061
10.
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions
by Wong, Benjamin C Y
Gut, 2012, Vol.61 (6), p.812-818
11.
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori
by Tsujimae, Masahiro
Digestion, 2016, Vol.94 (4), p.240-246
12.
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment
by Mougari, Faiza
Expert review of anti-infective therapy, 2016, Vol.14 (12), p.1139-1154
13.
14.
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
by Jacobson, Terry A
The American journal of cardiology, 2004, Vol.94 (9), p.1140-1146
15.
Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients
by Park, H. G.
Alimentary pharmacology & therapeutics, 2012, Vol.35 (1), p.56-65
16.
A trial of clarithromycin for the treatment of suboptimally controlled asthma
by Sutherland, E. Rand, MD, MPH
Journal of allergy and clinical immunology, 2010, Vol.126 (4), p.747-753
17.
Systematic review and meta‐analysis: full‐ vs. half‐dose anti‐microbials in clarithromycin‐based regimens for Helicobacter pylori eradication
by Harb, A. H.
Alimentary pharmacology & therapeutics, 2015, Vol.42 (2), p.131-141
18.
Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo‐controlled study
by Lane, J. A.
Alimentary pharmacology & therapeutics, 2011, Vol.33 (8), p.922-929
19.
Randomised clinical trial: the efficacy of a 10‐day sequential therapy vs. a 14‐day standard proton pump inhibitor‐based triple therapy for Helicobacter pylori in Korea
by Kim, Y. S.
Alimentary pharmacology & therapeutics, 2011, Vol.34 (9), p.1098-1105
20.
Helicobacter pylori and antibiotic resistance
by Megraud, Francis
Gut, 2007, Vol.56 (11), p.1502-1502
